15.12.2015 • News

AstraZeneca Confirms Talks with Acerta

AstraZeneca has confirmed speculation that it is “exploring potential strategic options” with Acerta Pharma, a privately owned biotech firm with operations in the Netherlands and California.

However, the British-Swedish drugmaker said, “there can be no certainty that any transaction will ultimately be entered into, or as to the terms of any transaction.” It added it would make a further announcement “if and when appropriate.”

Earlier, the US newspaper Wall Street Journal had reported that AstraZeneca had offered to buy Acerta for more than $5 billion to gain access to its experimental blood cancer drug acalabrutinib.

Acerta is currently developing acalabrutinib, also known as ACP-196, for the treatment of various malignancies, including leukemias and lymphomas. Data from recent Phase I/II trials is said to have shown that the Bruton tyrosine kinase (BTK) inhibitor was associated with a response rate of 95% among patients with relapsed chronic lymphocytic leukemia.

Acalabrutinib is said to work in a similar way to Imbruvica, developed by Pharmacyclics. That company was snapped up for $21 billion earlier this year by AbbVie, which currently co-markets the drug with Johnson & Johnson.

Both products target a variety of blood cancers and are regarded as having the potential to become multibillion-dollar-a-year blockbusters, especially as they may also help treat autoimmune diseases such as lupus.

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.